Featured Research

from universities, journals, and other organizations

'Trojan Horse' particle sneaks chemotherapy in to kill ovarian cancer cells

Date:
September 12, 2011
Source:
Biotechnology and Biological Sciences Research Council
Summary:
A common chemotherapy drug has been successfully delivered to cancer cells inside tiny microparticles using a method inspired by our knowledge of how the human immune system works. The drug, delivered in this way, reduced ovarian cancer tumors in an animal model by 65 times more than using the standard method. This approach is now being developed for clinical use.

Cancer cell (red and blue nucleus) that ingested two large microparticles (green).
Credit: Dr Davidson Ateh, BioMoti Limited

A common chemotherapy drug has been successfully delivered to cancer cells inside tiny microparticles using a method inspired by our knowledge of how the human immune system works. The drug, delivered in this way, reduced ovarian cancer tumours in an animal model by 65 times more than using the standard method. This approach is now being developed for clinical use.

Related Articles


The research was funded by, among others, the Biotechnology and Biological Sciences Research Council (BBSRC) Follow-on Fund -- funding for 'proof of concept' at the very early stage of turning research outputs into a commercial proposition -- and carried out at Queen Mary, University of London. The study will be published next week in the journal, Biomaterials.

Dr Davidson Ateh, who worked on the research at Queen Mary, University of London and set up the start-up company, BioMoti, that will develop the technology for clinical use said "It's like we've made a re-enactment of the battle of Troy but on the tiniest scale. In Troy, the Greeks fooled the Trojans into accepting a hollow horse full of soldiers -- we've managed to trick cancer cells into accepting drug-filled microparticles."

Dr Ateh and colleagues found that by coating tiny microparticles of around a hundredth the diameter of a human hair with a special protein called CD95, they could in fact trigger cancer cells into ingesting these particles. Not only that, but the particles could deliver a dose of a common chemotherapy drug called paclitaxel.

The key to their success is that CD95 attaches to another protein called CD95L, which is found much more commonly on the surface of cancer cells than it is on normal healthy cells.

Once attached, the cancer cells ingest CD95 and the microparticle with it.

Inside the cell, the microparticle can unload its chemotherapy cargo, which kills the cell to reduce the size of the tumour.

Dr Ateh added "Other researchers had already noticed that cancer cells may use this CD95-CD95L arrangement to avoid being destroyed by the immune system, which is why they display more CD95L than normal cells. We've managed to turn this to our advantage and hijack the cancer cell's own trick-of-the-trade to get our 'Trojan Horse' through the gate."

Co-author and Professor of Gynecological Oncology at Queen Mary, University of London, Iain McNeish commented "Chemotherapy is still the main way that we treat ovarian cancer, which can be particularly aggressive and difficult to treat. Anything we can do to concentrate the treatment in tumour cells and at the same time protect healthy cells is a good thing. This is an elegant method and if it works in a clinical setting as well as we hope it will patients could experience a better treatment with fewer side effects."

Principal investigator and Professor of Pathology at Queen Mary, University of London, Joanne Martin added "There are lots of drugs that we would like to deliver into cells -- not just chemotherapies -- and this could work for those too. For example, there are new classes of drugs to treat tumours, such as biological therapies. If we could load biological therapies into the same CD95-coated particles, then there's no reason why they couldn't also be delivered in this way."

The researchers are now advancing these studies and BioMoti is seeking to attract larger and established pharmaceutical companies to partner the technology, dubbed OncoJanTM in reference to the earlier Trojan horse, for the clinical development of new treatments in specific types of cancer.

Professor Douglas Kell, Chief Executive, BBSRC said "BBSRC funds a great deal of work that is aimed at improving our fundamental understanding of biological processes. When there are opportunities to use this understanding to the benefit of people, it is vitally important to seize and make the most of them. This is a good example where research into the human immune system has led to a new technology that has the potential to underpin health and wellbeing into later life."


Story Source:

The above story is based on materials provided by Biotechnology and Biological Sciences Research Council. Note: Materials may be edited for content and length.


Journal Reference:

  1. Davidson D. Ateh, Veronica H. Leinster, Sally R. Lambert, Afsha Shah, Ayub Khan, Hazel J. Walklin, Jennifer V. Johnstone, Nader I. Ibrahim, Mustafa M. Kadam, Zain Malik, Mνriam Gironθs, Gert J. Veldhuis, Gary Warnes, Silvia Marino, Iain A. McNeish, Joanne E. Martin. The intracellular uptake of CD95 modified paclitaxel-loaded poly(lactic-co-glycolic acid) microparticles. Biomaterials, 2011; DOI: 10.1016/j.biomaterials.2011.07.060

Cite This Page:

Biotechnology and Biological Sciences Research Council. "'Trojan Horse' particle sneaks chemotherapy in to kill ovarian cancer cells." ScienceDaily. ScienceDaily, 12 September 2011. <www.sciencedaily.com/releases/2011/09/110912102122.htm>.
Biotechnology and Biological Sciences Research Council. (2011, September 12). 'Trojan Horse' particle sneaks chemotherapy in to kill ovarian cancer cells. ScienceDaily. Retrieved April 1, 2015 from www.sciencedaily.com/releases/2011/09/110912102122.htm
Biotechnology and Biological Sciences Research Council. "'Trojan Horse' particle sneaks chemotherapy in to kill ovarian cancer cells." ScienceDaily. www.sciencedaily.com/releases/2011/09/110912102122.htm (accessed April 1, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Wednesday, April 1, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

7-Year-Old Girl Gets 3-D Printed 'robohand'

7-Year-Old Girl Gets 3-D Printed 'robohand'

AP (Mar. 31, 2015) — Although she never had much interest in prosthetic limbs before, Faith Lennox couldn&apos;t wait to slip on her new robohand. The 7-year-old, who lost part of her left arm when she was a baby, grabbed it as soon as it came off a 3-D printer. (March 31) Video provided by AP
Powered by NewsLook.com
Solitair Device Aims to Takes Guesswork out of Sun Safety

Solitair Device Aims to Takes Guesswork out of Sun Safety

Reuters - Innovations Video Online (Mar. 31, 2015) — The Solitair device aims to take the confusion out of how much sunlight we should expose our skin to. Small enough to be worn as a tie or hair clip, it monitors the user&apos;s sun exposure by taking into account their skin pigment, location and schedule. Matthew Stock reports. Video provided by Reuters
Powered by NewsLook.com
Soda, Salt and Sugar: The Next Generation of Taxes

Soda, Salt and Sugar: The Next Generation of Taxes

Washington Post (Mar. 30, 2015) — Denisa Livingston, a health advocate for the Dinι Community Advocacy Alliance, and the Post&apos;s Abby Phillip discuss efforts around the country to make unhealthy food choices hurt your wallet as much as your waistline. Video provided by Washington Post
Powered by NewsLook.com
UnitedHealth Buys Catamaran

UnitedHealth Buys Catamaran

Reuters - Business Video Online (Mar. 30, 2015) — The $12.8 billion merger will combine the U.S.&apos; third and fourth largest pharmacy benefit managers. Analysts say smaller PBMs could also merge. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins